The antibody development platform established by our company possesses independent intellectual property rights, which, like a rich mineral deposit, contains large-capacity, diversified 1011 fully-humanized phage display antibody library and the 1010 synthetic nanobody library. This platform can satisfy the development needs of antibodies and CAR T-cell drugs for different indications. A series of high-affinity fully-humanized antibody drug candidate molecules, such as anti-BCMA, GPC-3, PD-L1, IL-17, and 4-1BB antibodies and ScFv- and VH-based CAR-T cells with synergistic effects have been successfully developed.
There are two major development strategies for our antibody platform. One is to provide targets with a good synergistic effect for CAR-T products, enhancing competitive advantages enjoyed by the company's CAR-T products; the other is to further develop suitable CAR-T targets into antibody drug candidates, so as to yield profits and increase the value of the company through the authorization or cooperative development.